WebNov 10, 2024 · A typical adverse reaction of daptomycin is creatine phosphokinase (CPK) elevation, which occurred in 6.7% of patients in a phase 3 study [ 2 ]. This adverse reaction is dose-dependent, and Lai et al reported a significantly higher incidence of CPK elevation at doses of ≥8mg/kg than at <8mg/kg [ 3 ]. WebMay 18, 2024 · Daptomycin is the antibiotic most strongly associated with rhabdomyolysis, with rhabdomyolysis cases totaling 5.5% of daptomycin reports to FAERS, the FDA Adverse Event Reporting System. ... It has been suggested that decreased perioperative fluid administration may decrease the incidence of rhabdomyolysis in the bariatric surgery …
Comparison of the efficacy and safety of standard‐ and high‐dose ...
WebFactors conferring increased risk for daptomycin-associated myopathy or rhabdomyolysis include : … Overview of the causes and treatment of hyperphosphatemia … lysis syndrome, muscle necrosis ( rhabdomyolysis ), and, rarely, marked hemolysis or … WebNov 23, 2024 · Citation 8 In contrast, a study by Graham et al Citation 9 in 2004 reported an average incidence of 0.44 in 10,000 patients (who developed rhabdomyolysis) being treated with atorvastatin, simvastatin, or pravastatin, with a 95% confidence interval of 0.20–0.84. These patients had been taking lipid-lowering agents alone or in combination. photo photo viewer
Efficacy and Safety of Daptomycin in Patients with Renal
WebSep 29, 2024 · Daptomycin use is a known cause of rhabdomyolysis; its role in liver injury is less certain. We report a case of daptomycin-induced rhabdomyolysis with liver injury. WebSep 29, 2024 · Introduction. Daptomycin is a lipopeptide antibiotic often used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). Despite its clinical utility, there have been a few reports of rhabdomyolysis related to daptomycin use [1,2].In this report, we present a case of rhabdomyolysis, severe hyperkalemia, and acute kidney injury … WebJun 15, 2006 · The use of daptomycin has been associated with an elevation in creatine phosphokinase level, with a reported incidence of 2.8% in phase III clinical trials. Published case reports have documented the presence of myopathy in patients who received … photo photo booth